MedPath

Mitochondrial Metabolism and Hepatic Complications of Obesity

Not Applicable
Withdrawn
Conditions
Obesity
Interventions
Other: liver biopsy
Registration Number
NCT03302481
Lead Sponsor
Nantes University Hospital
Brief Summary

The study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis.

Detailed Description

The study aims to characterize mitochondrial metabolism in the liver of obesity surgery patients and to study its relationships with hepatic steatosis, inflammation, and fibrosis. The protocols involves a per-operative hepatic needle biopsy for mitochondria characterization and histological scoring of steatosis, inflammation, and fibrosis

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • adult men and women
  • affiliated to a social security
  • candidate for laparoscopic obesity surgery
Read More
Exclusion Criteria
  • Excessive alcohol consumption:> 20 g / day (woman),> 30 g / day (male)
  • Chronic viral hepatitis B or C
  • Genetic hemochromatosis
  • Taking the following drugs for at least 3 months up to 6 months before the scheduled date of obesity surgery: systemic corticosteroids, amiodarone, methotrexate
  • Wilson's disease
  • autoimmune hepatitis
  • alpha 1-antitrypsin deficiency
  • abetalipoproteinemia
  • Contraindications to liver biopsy
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Experimental Groupliver biopsythe biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
Primary Outcome Measures
NameTimeMethod
Association between nonalcoholic steato-hepatitis and mitochondria morphological markersUntil 6 month
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath